Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
December 13, 2024 18:50 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British…
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”)…
Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
December 13, 2024 03:00 ET | Source: Actimed Therapeutics London, UK –…
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 12, 2024 06:00 ET | Source: Keros Therapeutics, Inc. Keros will…
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR…
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included…
Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included…
InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO
NEWARK, Calif.--(BUSINESS WIRE)--#AFIB--InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics…
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
MTL-HBG drug candidate demonstrated best-in-class activity and safety in pre-clinical models Data…
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
A 30% reduction in long episodes was shown to be associated with…